Center of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Vip Ward, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Clin Chim Acta. 2018 May;480:199-205. doi: 10.1016/j.cca.2018.02.019. Epub 2018 Feb 19.
Circulating long noncoding RNA (lncRNA) H19 has been reported to be a biomarker for cancer monitoring. The purpose of this study was to determine whether serum lncRNA could serve as a novel biomarker for the diagnosis of multiple myeloma (MM) and evaluate its value of clinical application. In our study, the expression of lncRNA H19 was up-regulated in 80 patients with MM and MM cell lines by RT-PCR analysis. Clinicopathological analysis showed the expression level of H19 could assist clinical staging, and the severity of the disease could be roughly determined according to the amount of H19 expressed in the patient serum. This is the first report to show that H19 was expressed in the serum of MM patients, suggesting that upregulation of serum lncRNA H19 may prove to be a novel biomarker for early diagnosis and clinical treatment of MM.
循环长非编码 RNA（lncRNA）H19 已被报道可作为癌症监测的生物标志物。本研究旨在确定血清 lncRNA 是否可作为多发性骨髓瘤（MM）诊断的新型生物标志物，并评估其临床应用价值。在我们的研究中，通过 RT-PCR 分析发现 80 例 MM 患者和 MM 细胞系中 lncRNA H19 的表达上调。临床病理分析表明，H19 的表达水平可辅助临床分期，根据患者血清中 H19 的表达量大致可判断疾病的严重程度。这是首次报道 H19 在 MM 患者的血清中表达，提示血清 lncRNA H19 的上调可能被证明是 MM 早期诊断和临床治疗的新型生物标志物。
